Claire Cropet

28, Rue Laennec
Lyon, 69008, France

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 60 publications

Twenty-five years survival of primary central nervous system lymphomas treated with the C5R regimen.

Twenty-five years survival of primary central nervous system lymphomas treated with the C5R regimen.

Journal: European journal of cancer (Oxford, England : 1990)

Published: June 17, 2026

Response to Yu, Wang and Ge.

Response to Yu, Wang and Ge.

Journal: Journal of the National Cancer Institute

Published: June 15, 2026

Durvalumab combined with weekly carboplatin/paclitaxel as first-line treatment of patients with recurrent and/or metastatic HNSCC not eligible for cisplatin-based chemotherapies: results of the multicenter prospective study FRAIL-IMMUNE.

Durvalumab combined with weekly carboplatin/paclitaxel as first-line treatment of patients with recurrent and/or metastatic HNSCC not eligible for cisplatin-based chemotherapies: results of the multicenter prospective study FRAIL-IMMUNE.

Journal: ESMO open

Published: January 07, 2026

COVID-19 vaccination before immune checkpoint inhibitor initiation and the overall survival of patients with advanced cancer: A cohort study.

COVID-19 vaccination before immune checkpoint inhibitor initiation and the overall survival of patients with advanced cancer: A cohort study.

Journal: European journal of cancer (Oxford, England : 1990)

Published: December 19, 2025

Reply to Letter to the Editor "Long-term follow-up of PAOLA-1 and the evolving landscape of post-PARP treatment strategies in ovarian cancer" by Arenhardt and Nogueira-Rodrigues.

Reply to Letter to the Editor "Long-term follow-up of PAOLA-1 and the evolving landscape of post-PARP treatment strategies in ovarian cancer" by Arenhardt and Nogueira-Rodrigues.

Journal: Annals of oncology : official journal of the European Society for Medical Oncology

Published: June 24, 2025

Tremelimumab plus durvalumab combined to metronomic oral vinorelbine: Results from the breast cancer cohort of the phase II MOVIE study.

Tremelimumab plus durvalumab combined to metronomic oral vinorelbine: Results from the breast cancer cohort of the phase II MOVIE study.

Journal: Breast (Edinburgh, Scotland)

Published: April 29, 2025

Vaginal germ cell tumors: results from the international retrospective VAGIPED study.

Vaginal germ cell tumors: results from the international retrospective VAGIPED study.

Journal: British journal of cancer

Published: April 14, 2025

MOVIE phase II trial of tremelimumab plus durvalumab combined with metronomic oral vinorelbine in patients with head and neck cancer.

MOVIE phase II trial of tremelimumab plus durvalumab combined with metronomic oral vinorelbine in patients with head and neck cancer.

Journal: ESMO open

Published: January 21, 2025

Durvalumab and tremelimumab in combination with metronomic oral vinorelbine for recurrent advanced cervical cancer: an open-label phase I/II study.

Durvalumab and tremelimumab in combination with metronomic oral vinorelbine for recurrent advanced cervical cancer: an open-label phase I/II study.

Journal: Journal for immunotherapy of cancer

Published: November 25, 2024

Efficacy of subsequent therapies in patients with advanced ovarian cancer who relapse after first-line olaparib maintenance: results of the PAOLA-1/ENGOT-ov25 trial.

Efficacy of subsequent therapies in patients with advanced ovarian cancer who relapse after first-line olaparib maintenance: results of the PAOLA-1/ENGOT-ov25 trial.

Journal: Annals of oncology : official journal of the European Society for Medical Oncology

Published: August 05, 2024

Nivolumab plus ipilimumab versus carboplatin-based doublet as first-line treatment for patients with advanced non-small-cell lung cancer aged ≥70 years or with an ECOG performance status of 2 (GFPC 08-2015 ENERGY): a randomised, open-label, phase 3 study.

Nivolumab plus ipilimumab versus carboplatin-based doublet as first-line treatment for patients with advanced non-small-cell lung cancer aged ≥70 years or with an ECOG performance status of 2 (GFPC 08-2015 ENERGY): a randomised, open-label, phase 3 study.

Journal: The Lancet. Respiratory medicine

Published: May 16, 2024

Safety and quality of life with maintenance olaparib plus bevacizumab in older patients with ovarian cancer: subgroup analysis of PAOLA‑1/ENGOT-ov25.

Safety and quality of life with maintenance olaparib plus bevacizumab in older patients with ovarian cancer: subgroup analysis of PAOLA‑1/ENGOT-ov25.

Journal: The oncologist

Published: March 05, 2024

Showing 1-12 of 60

Last Updated: 09/26/2026